Add BrightSurf on Google Email

Effectiveness of using siRNA to treat Huntington’s disease

A new study published in Nucleic Acid Therapeutics found that siRNA reduces huntingtin mRNA levels in the cytoplasm but not in the nucleus of mouse brains, suggesting a limitation in its effectiveness for treating Huntington's disease. The research highlights the importance of understanding the structure and function of nuclear RNA to ...

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·TypeExperimental study·DateJul 22, 2024

Scientists pinpoint new drug target for RSV

Scientists at Trinity College Dublin have identified a key biological pathway, the JAK/STAT pathway, that RSV suppresses and prevents immune system igniters from activating. This discovery provides a promising new target for therapeutic immune restoration and could lead to significant impact in treating RSV infections.

SourceTrinity College Dublin·JournalFrontiers in Immunology·DateJul 19, 2024

New Surgical Infection Society guidelines on the management of intra-abdominal infection

The new guidelines from the Surgical Infection Society offer updated recommendations for antimicrobial agent selection, source control, and treatment of specific pathogens. These evidence-based guidelines aim to improve clinical outcomes and reduce mortality rates from intra-abdominal infections globally.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalSurgical Infections·TypeSystematic review·DateJul 18, 2024

Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer

Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateJul 17, 2024

Off-the-shelf wearable trackers provide clinically-useful information for patients with heart disease

A study published in Nature Medicine found that off-the-shelf wearable trackers can monitor the response to two treatments for atrial fibrillation and heart failure. The devices provided clinically useful information similar to in-person hospital assessments, with a neural network helping to analyze missing data.

SourceUniversity of Birmingham·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJul 15, 2024

A new study reveals the underuse of a key drug in patients with treatment-resistant schizophrenia

A new study analyzed clozapine prescription patterns in patients with first-episode psychosis, finding that approximately 20-30% do not respond to conventional treatments. The use of clozapine can significantly reduce psychotic symptoms and improve quality of life for these patients.

SourceGermans Trias i Pujol Research Institute·JournalSpanish Journal of Psychiatry and Mental Health·TypeExperimental study·DateJul 11, 2024

Researchers find intriguing new tool for tendon healing: nanoparticles for precision drug delivery

A team of researchers has created a new approach to deliver drugs precisely to surgically repaired tendons using nanoparticles, reducing scar tissue formation and improving function. The treatment targets the Acp5 gene, which is highly expressed at the injury site, and delivers medication directly to the healing tendon.

SourceUniversity of Rochester Medical Center·JournalScience Advances·DateJun 27, 2024

AI-based Alphafold: Its potential impact on predictive medicine

AlphaFold's groundbreaking ability to predict protein structures is set to transform predictive medicine, enabling the development of personalized vaccines and adaptive clinical trials. However, the review also highlights crucial challenges and ethical considerations surrounding AI integration with clinical data.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalAI in Precision Oncology·TypeLiterature review·DateJun 26, 2024

Korea University identifies novel inhibitor HVH-2930 showing promise in overcoming trastuzumab resistance in HER2-positive breast cancer

A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.

SourceKorea University College of Medicine·JournalTheranostics·TypeExperimental study·DateJun 25, 2024

Standardized protocols help hospitals treat strokes faster, WVU research finds

Researchers found that hospitals that implemented standardized protocols from the American Heart Association and American Stroke Association saw significant reductions in stroke treatment times. The protocols, which include specific limits on time between symptom onset and hospital arrival, helped medical teams respond more quickly to ...

SourceWest Virginia University·JournalJournal of Operations Management·DateJun 24, 2024

Dietary sucrose determines activity of lithium on gene expression and lifespan in drosophila melanogaster

Researchers found that lithium's efficacy in enhancing longevity and altering body composition is influenced by the sucrose content of the diet. The study reveals a significant overlap between the transcriptional responses to increasing dietary sucrose and adding lithium, suggesting a joint mechanism at play.

SourceImpact Journals LLC·JournalAging-US·TypeExperimental study·DateJun 20, 2024

More effective cancer treatment with iontronic pump

Researchers at Linköping University and the Medical University of Graz have developed a new cancer treatment using an iontronic pump to deliver continuous, low-dose chemotherapy directly to brain tumors. This approach significantly reduces tumor growth by bypassing the blood-brain barrier, a common obstacle to effective treatment.

SourceLinköping University·JournalJournal of Controlled Release·TypeExperimental study·DateJun 19, 2024

New study reveals combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer’s disease patients

A new study led by Chapman University researchers found that combining Donepezil and Memantine significantly increased the probability of five-year survival for Alzheimer's disease patients. The combined use of these two medications reduced mortality rates by 0.05, or 6.4%, compared to no treatment and single-drug use.

SourceChapman University·JournalCommunications Medicine·DateJun 12, 2024

FAP-targeted therapy demonstrates significant efficacy in controlling advanced sarcomas

Researchers found that FAP-targeted radioligand therapy controlled disease progression in nearly half of patients with advanced sarcoma, and was well-tolerated without critical organ radiation dose levels being reached. The study's results indicate a promising approach for this patient group with limited treatment options.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJun 8, 2024

Breaking down barriers: ROCK2 inhibition facilitates drug delivery in fibrotic pancreatic cancer

Researchers developed a human pancreatic cancer fibrotic barrier model to assess treatment strategies and test efficacy of therapeutic interventions. Inhibition of ROCK2 pathway resulted in reduced ECM remodeling and improved tissue permeability for drugs, highlighting its potential for enhancing drug delivery in PDAC.

SourceOkayama University·JournalJournal of Controlled Release·TypeExperimental study·DateJun 5, 2024

White blood cell “nets” could be early warning sign of major immunotherapy complication

A study from Michigan Medicine reveals a connection between neutrophil activation and severe cytokine release syndrome (CRS), a potentially life-threatening reaction to CAR T-Cell therapy. Researchers identified biomarkers of NETosis, a process in which neutrophils create webs that may contribute to CRS.

SourceMichigan Medicine - University of Michigan·JournalBlood Advances·TypeExperimental study·DateJun 3, 2024

Optimal cancer-killing t cells discovered

Researchers at the University of Houston have identified a subset of T cells called CD8-fit that show high motility and serial killing capabilities in patients with clinical responses. These cells were discovered using a patented approach called TIMING, which evaluates cell behavior and movement to identify potential cancer-killing cells.

SourceUniversity of Houston·JournalNature Cancer·DateMay 28, 2024

Diagnosis of lymphatic metastasis in breast cancer using nanoparticle technology - diagnosis, therapy, imaging, treatment

Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.

SourceBentham Science Publishers·JournalThe Open Neuroimaging Journal·DateMay 27, 2024